Pharmacological characterization of tardive dyskinesia
- Daniel E. CaseyAffiliated withDepartment of Psychiatry, Veterans Administration Hospital, Brown UniversityDepartment of Medical Research, Veterans Administration HospitalUniversity of Oregon Health Sciences Center
- , Duane DenneyAffiliated withDepartment of Psychiatry, University of Oregon Health Sciences Center
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Tardive dyskinesia (TD) may be a clinical manifestation of a relative imbalance between the inversely related dopaminergic (DA) and acetylcholinergic (ACh) influences in the central nervous system (CNS). Six patients were evaluated with single challenge doses of a DA agonist, levodopa, and antagonist, droperidol, as well as with an ACh agonist, physostigmine, an antagonist, benztropine, and a placebo. A single blind trial with deanol and placebo followed. Responses, measured by an electrophysiological technique, formed two subgroups. The patients who improved with a DA antagonist or an ACh agonist improved while taking deanol. Another group of patients were made worse with a DA antagonist or ACh agonist and were worsened or had no response while taking deanol. While the results add support to the concept of counterbalancing DA-ACh influences in TD, further investigation of TD subtypes and predictors of drug response is warranted.
Key wordsTardive dyskinesia Dopamine Acetylcholine Levodopa Droperidol Physostigmine Benztropine Deanol
- Pharmacological characterization of tardive dyskinesia
Volume 54, Issue 1 , pp 1-8
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Tardive dyskinesia
- Industry Sectors
- Author Affiliations
- 1. Department of Psychiatry, Veterans Administration Hospital, Brown University, Providence, Rhode Island, U.S.A.
- 2. Department of Medical Research, Veterans Administration Hospital, Portland, Oregon, U.S.A.
- 3. University of Oregon Health Sciences Center, Portland, Oregon, U.S.A.
- 5. Department of Psychiatry, University of Oregon Health Sciences Center, Portland, Oregon, U.S.A.